Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.69 USD | +2.69% | +5.95% | +17.09% |
May. 09 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 452
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vonoprazan
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Azmi Nabulsi
FOU | Founder | 64 | 18-01-08 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 19-07-31 |
David Socks
FOU | Founder | 49 | 18-01-08 |
Molly Henderson
DFI | Director of Finance/CFO | 54 | 22-04-04 |
Chief Tech/Sci/R&D Officer | 60 | 19-12-01 | |
Eric Sciorilli
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | 20-01-05 | |
Tom Harris
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Fields
BRD | Director/Board Member | 69 | 19-09-26 |
Frank Karbe
BRD | Director/Board Member | 55 | 22-04-24 |
Michael Cola
CHM | Chairman | 64 | 19-09-26 |
James Topper
BRD | Director/Board Member | 62 | 17-12-31 |
David Socks
FOU | Founder | 49 | 18-01-08 |
Terrie Curran
CEO | Chief Executive Officer | 55 | 19-07-31 |
Asit Parikh
BRD | Director/Board Member | 52 | 19-11-30 |
Mark Stenhouse
BRD | Director/Board Member | 57 | 20-03-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,554,193 | 52,894,648 ( 90.33 %) | 0 | 90.33 % |
Company contact information
Phathom Pharmaceuticals, Inc.
100 Campus Drive Suite 102
07932, Florham Park
+
http://www.phathompharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.09% | 609M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- PHAT Stock
- Company Phathom Pharmaceuticals, Inc.